Fresenius Kabi receives European Commission approval for adalimumab biosimilar IDACIO®

The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

The release as fetched from its publisher. fresenius.com ↗